Curatis Holding AG is a specialty pharmaceutical company. It focuses on the acquisition, development and commercialisation of medicines for the prevention, diagnosis and treatment of rare and specialty-care diseases. Curatis operates a distribution business for third-party orphan and specialty medicines in Switzerland and pursues drug development through a pipeline of selected candidates.
AI-generated
Offering
Products & services
Industry:Holding Companies
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Pharmaceutical distribution and marketing in Switzerland, in particular for rare and special diseases as well as intoxications; integration of own products and products from international partner companies.
Development of medicines for rare and special diseases
Development of novel special and orphan medicines, with projects on peritumoral cerebral edema, severe migraine with aura, medication-overuse headache as well as fibrotic or inflammatory orphan diseases.
Commercial partnerships for Switzerland
Commercial partnerships for pharmaceutical products in Switzerland, covering market access, registration, pricing, reimbursement, marketing, sales, early-access programs, as well as pharmacovigilance and quality processes.
Commercial partnerships for Germany, France, Italy and the UK
Search for distribution partnerships for Ultra-Orphan, Orphan and Specialty-Care medicines in Germany, France, Italy and the United Kingdom.